Viridian Therapeutics (VRDN) Revenue & Revenue Breakdown
Viridian Therapeutics Revenue Highlights
Latest Revenue (Y)
$314.00K
Latest Revenue (Q)
$72.00K
Main Segment (Y)
Collaboration Revenue
Viridian Therapeutics Revenue by Period
Viridian Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $314.00K | -82.28% |
| 2022-12-31 | $1.77M | -40.20% |
| 2021-12-31 | $2.96M | 182.19% |
| 2020-12-31 | $1.05M | -76.46% |
| 2019-12-31 | $4.46M | -46.80% |
| 2018-12-31 | $8.39M | 109.49% |
| 2017-12-31 | $4.00M | 19.96% |
| 2016-12-31 | $3.34M | 31.48% |
| 2015-12-31 | $2.54M | -41.25% |
| 2014-12-31 | $4.32M | 0.08% |
| 2013-12-31 | $4.32M | -2.03% |
| 2012-12-31 | $4.41M | - |
Viridian Therapeutics generated $314.00K in revenue during NA 2023, up -82.28% compared to the previous quarter, and up 3.74% compared to the same period a year ago.
Viridian Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $72.00K | - |
| 2024-03-31 | $72.00K | - |
| 2023-12-31 | $72.00K | - |
| 2023-09-30 | $72.00K | - |
| 2023-06-30 | $72.00K | -26.53% |
| 2023-03-31 | $98.00K | -6.67% |
| 2022-12-31 | $105.00K | -91.21% |
| 2022-09-30 | $1.20M | 366.80% |
| 2022-06-30 | $256.00K | 18.52% |
| 2022-03-31 | $216.00K | 0.93% |
| 2021-12-31 | $214.00K | 2.88% |
| 2021-09-30 | $208.00K | -80.92% |
| 2021-06-30 | $1.09M | -24.88% |
| 2021-03-31 | $1.45M | 2587.04% |
| 2020-12-31 | $54.00K | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $168.00K | -79.71% |
| 2020-03-31 | $828.00K | -5.91% |
| 2019-12-31 | $880.00K | 26.62% |
| 2019-09-30 | $695.00K | -72.35% |
| 2019-06-30 | $2.51M | 575.81% |
| 2019-03-31 | $372.00K | -21.85% |
| 2018-12-31 | $476.00K | -49.58% |
| 2018-09-30 | $944.00K | -56.74% |
| 2018-06-30 | $2.18M | -54.39% |
| 2018-03-31 | $4.78M | 301.34% |
| 2017-12-31 | $1.19M | -26.92% |
| 2017-09-30 | $1.63M | 127.16% |
| 2017-06-30 | $718.00K | 55.41% |
| 2017-03-31 | $462.00K | -38.89% |
| 2016-12-31 | $756.00K | -14.96% |
| 2016-09-30 | $889.00K | 1.72% |
| 2016-06-30 | $874.00K | 6.85% |
| 2016-03-31 | $818.00K | 24.13% |
| 2015-12-31 | $659.00K | 31.54% |
| 2015-09-30 | $501.00K | -31.74% |
| 2015-06-30 | $734.00K | 13.80% |
| 2015-03-31 | $645.00K | -1.45% |
| 2014-12-31 | $654.52K | -49.69% |
| 2014-09-30 | $1.30M | 2.15% |
| 2014-06-30 | $1.27M | 16.74% |
| 2014-03-31 | $1.09M | 0.03% |
| 2013-12-31 | $1.09M | 10.88% |
| 2013-09-30 | $983.59K | -10.82% |
| 2013-06-30 | $1.10M | -3.20% |
| 2013-03-31 | $1.14M | - |
Viridian Therapeutics generated $72.00K in revenue during Q2 2024, up 0.00% compared to the previous quarter, and up 73.47% compared to the same period a year ago.
Viridian Therapeutics Revenue Breakdown
Viridian Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Collaboration Revenue | $300.00K | $1.80M | $2.96M | $735.00K | - |
| Grant | - | - | - | $315.00K | - |
| Milestone Payments | - | - | - | - | - |
Viridian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $100.00K | - | $100.00K | $100.00K | $100.00K | $100.00K | $1.20M | $300.00K | $200.00K | $208.00K | - | - | $54.00K | - | $837.00K | $625.00K | $2.50M | $435.00K | - | - |
| Grant | - | - | - | - | - | - | - | - | - | - | - | - | - | $168.00K | $43.00K | $70.00K | $16.00K | - | - | - |
| Collaboration Revenue, Related Party | - | - | - | - | - | - | - | - | - | - | $1.09M | $1.45M | - | - | - | - | - | - | - | - |
| Reimbursement Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $700.00K | $837.00K | $625.00K | $2.50M | $435.00K | - |
| Milestone Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Viridian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaboration Revenue (100.00%).
Viridian Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| ACLX | Arcellx | $110.32M | $27.38M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRUS | Merus | $43.95M | $7.33M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| GPCR | Structure Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DICE | DICE Therapeutics | - | - |
| INZY | Inozyme Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| TERN | Terns Pharmaceuticals | - | - |
| ETNB | 89bio | - | - |
VRDN Revenue FAQ
What is Viridian Therapeutics’s yearly revenue?
Viridian Therapeutics's yearly revenue for 2023 was $314K, representing a decrease of -82.28% compared to 2022. The company's yearly revenue for 2022 was $1.77M, representing a decrease of -40.20% compared to 2021. VRDN's yearly revenue for 2021 was $2.96M, representing an increase of 182.19% compared to 2020.
What is Viridian Therapeutics’s quarterly revenue?
Viridian Therapeutics's quarterly revenue for Q2 2024 was $72K, a 0% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $72K, a 0% increase from the previous quarter (Q4 2023), and a -26.53% decrease year-over-year (Q1 2023). VRDN's quarterly revenue for Q4 2023 was $72K, a 0% increase from the previous quarter (Q3 2023), and a -31.43% decrease year-over-year (Q4 2022).
What is Viridian Therapeutics’s revenue growth rate?
Viridian Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -89.40%, and for the last 5 years (2019-2023) was -92.96%.
What are Viridian Therapeutics’s revenue streams?
Viridian Therapeutics's revenue streams in c 23 are Collaboration Revenue
What is Viridian Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Viridian Therapeutics was Collaboration Revenue. This segment made a revenue of $300K, representing 100.00% of the company's total revenue.